Theratechnologies Inc. (THTX)
USD 2.77
(-5.14%)
USD 2.77
(-5.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 98.63 Million USD | -14.84% |
| 2022 | 115.83 Million USD | 14.17% |
| 2021 | 101.45 Million USD | 4.68% |
| 2020 | 96.91 Million USD | 4.53% |
| 2019 | 92.72 Million USD | 21.81% |
| 2018 | 76.12 Million USD | 243.01% |
| 2017 | 22.19 Million USD | 93.11% |
| 2016 | 11.49 Million USD | -9.11% |
| 2015 | 12.64 Million USD | 27.52% |
| 2014 | 9.91 Million USD | 125.84% |
| 2013 | 4.39 Million USD | -31.9% |
| 2012 | 6.44 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 96.55 Million USD | -2.11% |
| 2024 Q3 | 89.38 Million USD | -4.3% |
| 2024 Q2 | 93.4 Million USD | -3.26% |
| 2023 Q3 | 98.39 Million USD | -10.77% |
| 2023 Q1 | 111.55 Million USD | -3.7% |
| 2023 Q4 | 98.63 Million USD | 0.25% |
| 2023 FY | 98.63 Million USD | -14.84% |
| 2023 Q2 | 110.26 Million USD | -1.15% |
| 2022 Q2 | 107 Million USD | 8.62% |
| 2022 Q4 | 115.83 Million USD | 1.68% |
| 2022 Q3 | 113.91 Million USD | 6.46% |
| 2022 FY | 115.83 Million USD | 14.17% |
| 2022 Q1 | 98.51 Million USD | -2.9% |
| 2021 FY | 101.45 Million USD | 4.68% |
| 2021 Q3 | 100.13 Million USD | 1.8% |
| 2021 Q1 | 94.67 Million USD | -2.31% |
| 2021 Q4 | 101.45 Million USD | 1.32% |
| 2021 Q2 | 98.36 Million USD | 3.89% |
| 2020 Q1 | 90 Million USD | -2.93% |
| 2020 FY | 96.91 Million USD | 4.53% |
| 2020 Q2 | 96.33 Million USD | 7.03% |
| 2020 Q3 | 92.97 Million USD | -3.48% |
| 2020 Q4 | 96.91 Million USD | 4.24% |
| 2019 Q3 | 78.04 Million USD | -1.55% |
| 2019 Q1 | 82.36 Million USD | 8.23% |
| 2019 Q2 | 79.27 Million USD | -3.75% |
| 2019 FY | 92.72 Million USD | 21.81% |
| 2019 Q4 | 92.72 Million USD | 18.8% |
| 2018 Q2 | 23.88 Million USD | 12.08% |
| 2018 FY | 76.12 Million USD | 243.01% |
| 2018 Q1 | 21.3 Million USD | -3.98% |
| 2018 Q4 | 76.1 Million USD | 5.24% |
| 2018 Q3 | 72.31 Million USD | 202.78% |
| 2017 Q4 | 22.19 Million USD | 22.48% |
| 2017 FY | 22.19 Million USD | 93.11% |
| 2017 Q3 | 18.11 Million USD | 9.49% |
| 2017 Q2 | 16.54 Million USD | 30.44% |
| 2017 Q1 | 12.68 Million USD | 10.4% |
| 2016 Q2 | 13.01 Million USD | 1.42% |
| 2016 FY | 11.49 Million USD | -9.11% |
| 2016 Q4 | 11.49 Million USD | -0.91% |
| 2016 Q3 | 11.59 Million USD | -10.88% |
| 2016 Q1 | 12.82 Million USD | 1.47% |
| 2015 Q3 | 14.57 Million USD | 0.66% |
| 2015 FY | 12.64 Million USD | 27.52% |
| 2015 Q2 | 14.47 Million USD | 39.89% |
| 2015 Q4 | 12.64 Million USD | -13.25% |
| 2015 Q1 | 10.35 Million USD | 4.39% |
| 2014 Q3 | 7.85 Million USD | 1.6% |
| 2014 Q2 | 7.72 Million USD | 75.12% |
| 2014 Q1 | 4.41 Million USD | 0.52% |
| 2014 FY | 9.91 Million USD | 125.84% |
| 2014 Q4 | 9.91 Million USD | 26.28% |
| 2013 Q2 | 4.55 Million USD | -27.48% |
| 2013 FY | 4.39 Million USD | -31.9% |
| 2013 Q4 | 4.39 Million USD | 0.77% |
| 2013 Q3 | 4.35 Million USD | -4.43% |
| 2013 Q1 | 6.28 Million USD | -2.49% |
| 2012 FY | 6.44 Million USD | 0.0% |
| 2012 Q4 | 6.44 Million USD | -54.38% |
| 2012 Q2 | 14.61 Million USD | -12.81% |
| 2012 Q1 | 16.75 Million USD | 4.68% |
| 2012 Q3 | 14.13 Million USD | -3.29% |
| 2011 Q1 | 18.56 Million USD | -0.34% |
| 2011 Q4 | 16 Million USD | -15.6% |
| 2011 Q3 | 18.96 Million USD | -5.83% |
| 2011 Q2 | 20.14 Million USD | 8.46% |
| 2010 Q4 | 18.63 Million USD | 1.86% |
| 2010 Q1 | 21.79 Million USD | -11.7% |
| 2010 Q2 | 22.94 Million USD | 5.27% |
| 2010 Q3 | 18.29 Million USD | -20.27% |
| 2009 Q4 | 24.68 Million USD | 0.75% |
| 2009 Q1 | 25.77 Million USD | 344.75% |
| 2009 Q2 | 27.01 Million USD | 4.81% |
| 2009 Q3 | 24.49 Million USD | -9.33% |
| 2008 Q3 | 10.31 Million USD | -10.62% |
| 2008 Q1 | 9.05 Million USD | 5.23% |
| 2008 Q2 | 11.54 Million USD | 27.44% |
| 2008 Q4 | 5.79 Million USD | -43.83% |
| 2007 Q2 | 5.93 Million USD | 3.51% |
| 2007 Q3 | 9 Million USD | 51.56% |
| 2007 Q1 | 5.73 Million USD | 0.86% |
| 2007 Q4 | 8.6 Million USD | -4.35% |
| 2006 Q2 | 4.16 Million USD | -8.05% |
| 2006 Q1 | 4.52 Million USD | 13.97% |
| 2006 Q3 | 5.1 Million USD | 22.54% |
| 2006 Q4 | 5.68 Million USD | 11.52% |
| 2005 Q3 | 3.09 Million USD | -5.84% |
| 2005 Q4 | 3.97 Million USD | 28.48% |
| 2005 Q2 | 3.28 Million USD | -27.86% |
| 2005 Q1 | 4.55 Million USD | 8.17% |
| 2004 Q1 | 5.25 Million USD | -37.34% |
| 2004 Q2 | 4.15 Million USD | -20.96% |
| 2004 Q3 | 2.43 Million USD | -41.44% |
| 2004 Q4 | 4.2 Million USD | 72.87% |
| 2003 Q2 | 9.45 Million USD | -0.82% |
| 2003 Q3 | 9.59 Million USD | 1.55% |
| 2003 Q1 | 9.52 Million USD | -7.21% |
| 2003 Q4 | 8.39 Million USD | -12.55% |
| 2002 Q4 | 10.26 Million USD | 8.55% |
| 2002 Q1 | 16.59 Million USD | -14.57% |
| 2002 Q2 | 9.38 Million USD | -43.47% |
| 2002 Q3 | 9.46 Million USD | 0.83% |
| 2001 Q1 | 15.86 Million USD | -3.62% |
| 2001 Q4 | 19.42 Million USD | 7.76% |
| 2001 Q3 | 18.02 Million USD | 31.49% |
| 2001 Q2 | 13.71 Million USD | -13.56% |
| 2000 Q1 | 1.86 Million USD | 30.47% |
| 2000 Q4 | 16.45 Million USD | 79.54% |
| 2000 Q3 | 9.16 Million USD | -3.95% |
| 2000 Q2 | 9.54 Million USD | 412.91% |
| 1999 Q4 | 1.42 Million USD | 12.18% |
| 1999 Q1 | 1.39 Million USD | -7.03% |
| 1999 Q3 | 1.27 Million USD | -6.28% |
| 1999 Q2 | 1.35 Million USD | -2.57% |
| 1998 Q2 | 1.78 Million USD | 20.97% |
| 1998 Q3 | 1.51 Million USD | -14.92% |
| 1998 Q4 | 1.49 Million USD | -1.4% |
| 1998 Q1 | 1.47 Million USD | -0.01% |
| 1997 Q4 | 1.47 Million USD | -2.39% |
| 1997 Q1 | 803.74 Thousand USD | 0.0% |
| 1997 Q3 | 1.51 Million USD | 73.64% |
| 1997 Q2 | 870.7 Thousand USD | 8.33% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 660.79 Million USD | 85.073% |
| Safety Shot Inc | 3.89 Million USD | -2434.375% |
| Cosmos Health Inc. | 30.25 Million USD | -226.052% |
| Cronos Group Inc. | 43.73 Million USD | -125.532% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 87.932% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -103.61% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 45.612% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -617.149% |
| ProPhase Labs, Inc. | 42.54 Million USD | -131.852% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1026.53% |
| Dynavax Technologies Corporation | 375.02 Million USD | 73.698% |
| Radius Health, Inc. | 804.29 Million USD | 87.736% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -972.558% |
| Alvotech | 1.88 Billion USD | 94.76% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -1506.603% |
| Alpha Teknova, Inc. | 38.55 Million USD | -155.866% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 27.933% |
| SCYNEXIS, Inc. | 55.45 Million USD | -77.888% |
| Harrow Health, Inc. | 241.75 Million USD | 59.198% |
| Biofrontera Inc. | 23.13 Million USD | -326.289% |
| DURECT Corporation | 30.4 Million USD | -224.406% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 79.765% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 79.087% |
| OptiNose, Inc. | 194.33 Million USD | 49.243% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -370.199% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 39.819% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -87.826% |
| SIGA Technologies, Inc. | 57.97 Million USD | -70.134% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 55.123% |
| Shineco, Inc. | 47.6 Million USD | -107.217% |
| Phibro Animal Health Corporation | 725.54 Million USD | 86.405% |
| Procaps Group S.A. | 462.06 Million USD | 78.653% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -603.459% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -44835.584% |
| Viatris Inc. | 27.21 Billion USD | 99.638% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -1506.603% |
| Rockwell Medical, Inc. | 30.88 Million USD | -219.406% |
| Incannex Healthcare Limited | 5.83 Million USD | -1591.921% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -9.139% |
| Tilray Brands, Inc. | 892.11 Million USD | 88.943% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 89.594% |
| PetIQ, Inc. | 645.22 Million USD | 84.713% |
| Silver Spike Investment Corp. | 3 Million USD | -3177.227% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 90.324% |
| Journey Medical Corporation | 56.49 Million USD | -74.585% |
| Alimera Sciences, Inc. | 107.35 Million USD | 8.118% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -362.751% |
| Assertio Holdings, Inc. | 148.41 Million USD | 33.539% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -5102.575% |
| Embecta Corp. | 2.03 Billion USD | 95.155% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1061.753% |
| Procaps Group, S.A. | 462.06 Million USD | 78.653% |
| PainReform Ltd. | 2.69 Million USD | -3565.515% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 43.11% |
| Hempacco Co., Inc. | 18.82 Million USD | -424.051% |
| Talphera, Inc. | 6.29 Million USD | -1468.188% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 85.994% |
| Alvotech | 1.88 Billion USD | 94.76% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 88.191% |
| Kamada Ltd. | 109.96 Million USD | 10.302% |
| Indivior PLC | 1.95 Billion USD | 94.945% |
| Currenc Group, Inc. | 177.67 Million USD | 44.484% |
| Evoke Pharma, Inc. | 9.64 Million USD | -922.369% |
| Flora Growth Corp. | 17.22 Million USD | -472.75% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1061.753% |
| Evolus, Inc. | 209.68 Million USD | 52.959% |
| HUTCHMED (China) Limited | 536.38 Million USD | 81.61% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 88.707% |
| Akanda Corp. | 12.66 Million USD | -678.593% |